NCT04953143

Brief Summary

Frequently patients with advanced liver disease experience physical and emotional symptoms during their hospitalization that can may cause a level of discomfort to both the patient and the family members that surround them. This study involves the early introduction of a team of clinicians that specialize in the lessening (palliation) of many of these discomforting symptoms. This team of clinicians is called the palliative care team and they focus on ways to improve pain and other symptom management and to assist patients and their families in coping with the physical, emotional and social issues associated with a diagnosis of advanced liver disease. The team consists of physicians and advance practice nurses who have been specially trained in the care of patients facing serious illness and their caregivers. The investigators are studying the feasibility of delivering this program, the acceptability and satisfaction with the program, and changes in the quality of life, illness understanding, and symptoms of hospitalized patients who receive the program and their caregivers. The study will use a series of questionnaires to measure the study participants' quality of life, physical symptoms, illness and prognostic understanding, and mood. Study questionnaires will be completed in the hospital, home or clinic. Qualitative interviews will be conducted with hepatology and palliative care clinicians as well as patients and caregivers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2021

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 7, 2021

Completed
6 months until next milestone

Study Start

First participant enrolled

January 14, 2022

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 16, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 16, 2022

Completed
Last Updated

June 27, 2023

Status Verified

June 1, 2023

Enrollment Period

7 months

First QC Date

June 28, 2021

Last Update Submit

June 25, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • LiverPal intervention refinement

    The investigators will conduct qualitative interviews with the patients and caregivers enrolled in the open pilot phase as well as LiverPal clinicians to elicit stakeholder feedback on the intervention. The qualitative component of the exit interviews will explore 1) patients', caregivers' and clinicians' perceptions of the acceptability and content of LiverPal; 2) any barriers or challenges to providing or receiving LiverPal; and 3) suggested modifications to LiverPal to improve its delivery in the inpatient setting

    Time Frame: Up to 1 year

Study Arms (1)

Pilot

EXPERIMENTAL

Inpatient longitudinal palliative care intervention that includes the following domains: * Therapeutic relationship: Developing trust and credibility with patients and their families * Symptom management: Proactive symptom management for common advanced liver disease symptoms including pain, fatigue, anorexia, breathlessness, depression and anxiety * Coping with illness: Introduction of strategies to improve adjustment and meaning in life; bolstering caregiver coping * Prognostic awareness and illness understanding: Assessing patients' level of prognostic awareness and discussing strategies to help patients cope with uncertainty * Treatment decision-making: Supporting patients and caregivers in their medical decision-making and assessing their values in decision-making * End-of-life care: Review/discuss selection of healthcare proxy, preferences for end-of-life care

Behavioral: LiverPal Intervention

Interventions

Inpatient longitudinal palliative care intervention \- Patients will complete baseline assessments and will be followed by the palliative care clinicians delivering the LiverPal intervention during each of their hospitalizations over a 3 month period LiverPal intervention domains include the following: * Therapeutic relationship * Symptom management * Coping with illness * Prognostic awareness and illness understanding * Treatment decision-making * End-of-life care

Pilot

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult (≥ 18 years old) with advanced liver disease defined as cirrhosis complicated by one of the following (new or ongoing) clinically-evidence decompensating events
  • Ascites (requiring diuretics or large volume paracenteses)
  • Hepatic encephalopathy (requiring medical therapy)
  • History of variceal bleed episode within 1 year of enrollment
  • Admitted to the general medicine service
  • Ability fo communicate in English and provide informed consent
  • Have a score ≥ 7 on the Short Portable Mental Status Questionnaire

You may not qualify if:

  • Patients with severe hepatic encephalopathy or any other comorbid condition which the primary medical team believes prohibits compliance with study procedures
  • Patients with advanced malignancies being treated with palliative intent
  • Patients already receiving specialty palliative care and/or hospice care
  • Caregiver Eligibility Criteria
  • A relative or friend of eligible patient, who lives with them and has in-person contact with them at least twice per week
  • Verbally fluent in English or able to complete questionnaires with the help of an interpreter
  • Age 18 or older
  • Clinician Selection: All palliative care clinicians who deliver the LiverPal intervention will participate in qualitative interviews. Inpatient clinicians who provided direct care to enrolled patients in either the inpatient or outpatient setting will also be eligible to participate in the qualitative interviews.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

MeSH Terms

Conditions

Liver Cirrhosis

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Instructor in Internal Medicine

Study Record Dates

First Submitted

June 28, 2021

First Posted

July 7, 2021

Study Start

January 14, 2022

Primary Completion

August 16, 2022

Study Completion

August 16, 2022

Last Updated

June 27, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will not share

Locations